However, comparing MMP-9 in ALS with an OND group helps assess the specificity of a biomarker by determining whether it can distinguish the target disease, in this case, ALS, from other neurological conditions with overlapping symptoms or if the biomarker reflects a broader neurogenerative or inflammatory processes. Here, MMP9 is linked to amyotrophic lateral sclerosis.